[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370642-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370642-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","treatment-of-ovarian-cancer-from-the-past-to-the-new-era-review","Treatment of ovarian cancer - From the past to the new era - Review","","Ovarian cancer is identified as the most lethal malignancy among female genital cancers, driven by non-specific symptoms, late-stage diagnosis, and poor prognosis. The review focuses on diagnostic accuracy and precision to improve overall survival. It surveys epidemiology, clinical presentation, etiology, risk factors, staging, and diagnostic techniques, then assesses therapeutic approaches including cytoreductive surgery and adjuvant treatments, emphasizing mechanisms of resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/treatment-of-ovarian-cancer-from-the-past-to-the-new-era-review/370642/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/treatment-of-ovarian-cancer-from-the-past-to-the-new-era-review/370642.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ovarian cancer difficult to diagnose early?","Question",{"text":63,"@type":64},"Non-specific or mild symptoms, delayed onset of symptoms, inadequate screening, and overlap with more common conditions often lead to advanced-stage diagnosis and diagnostic delays.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What topics does the review cover?",{"text":68,"@type":64},"The review covers epidemiology, clinical presentation, etiology, risk factors, staging, and diagnostic techniques, and also therapeutic approaches such as cytoreductive surgery and adjuvant treatments.",{"name":70,"@type":61,"acceptedAnswer":71},"How do newer therapies relate to resistance and outcomes?",{"text":72,"@type":64},"Advancements in molecular profiling support novel therapeutic agents used in clinical practice or under investigation, aiming to improve management and survival while addressing resistance mechanisms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370642,1790215838,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ONCOLOGY LETTERS 30: 384, 2025  \nTreatment of ovarian cancer: From the past to the new era (Review)  \nKHALEDALROSAN 1 , AMJAD Z. ALROSAN 1 , GHAITH B. HEILAT2 , ALAAF. ALROUSAN3 , OMAR S. GAMMOH4 , ABDELRAHIM ALQUDAH 1 , SABA MADAE'EN 1 and MOHAMMED J. ALROUSAN5  \n1  \nDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, 2  \nZarqa 13133, Jordan; Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan; 3Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan;  \n4  \nDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan; 5  \nDepartment of General surgery, King Fahad Specialist Hospital, Tabuk 47717, Saudi Arabia  \nReceived November 19, 2024; Accepted April 28, 2025  \nDOI: 10. 3892/ol.2025.15130  \nAbstract. Ovarian cancer is the most lethal malignancy among female genital cancers, primarily due to the non‑specific symptoms, late‑stage diagnosis and poor prognosis. Thus, there is a need for accurate and precise diagnostic methods to improve overall survival rates. The aim of the present review was to provide a comprehensive overview of ovarian cancer, including its epidemiology, clinical presentation, etiology, risk factors, staging and diagnostic techniques, in addition to examining the therapeutic approaches, including cytoreduc‑ tive surgery and adjuvant treatments, while highlighting the mechanisms of resistance to such interventions. Advancementsin molecular profiling and a deeper understanding of ovarian tumorigenesis have led to the introduction of novel therapeutic agents currently in clinical use or under clinical investigation. These innovations may improve the management of ovarian cancer, potentially improving survival outcomes.  \nContents  \n1. Introduction  \n2. Treatment of ovarian cancer  \n3. Novel treatment modalities  \n4. Future perspective and directions  \n5. Conclusion  \nCorrespondence to: Dr Khaled Alrosan, Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, 453J+5C5 Damascus Highway, Zarqa 13133, Jordan  \nE‑[mail: kalrosan@hu.edu.jo](mail: kalrosan@hu.edu.jo); [rousankhaled@yahoo.com](rousankhaled@yahoo.com)  \nKey words: ovarian cancer, chemotherapy, resistance, targeted therapy, re‑purposing therapy  \n1. Introduction  \nOvarian cancer is the seventh most common type of cancer in female patients (1‑4) and the third most common gynecological cancer, following cervical and uterine cancer (5) . Although ovarian cancer ranks eighth as a cause of cancer‑associated mortality in female patients globally (3,6), it is the most lethal among gynecological tumors (2,3,6,7) . Ovarian cancer has a lifetime risk of 1. 3%(6) with ~314,000 new cases and~207,000 mortalities globally each year, based on data from 2020 (8,9) . In the United States, >22,000 new cases of ovarian cancer are diagnosed each year, with 14,000 deaths attributed to the disease (1,10) . Ovarian cancer is uncommon in young patients, especially those \u003C30 years old; however, the risk rises with age, with a sharp increase in patients ≥50 years old (2) . There are also geographical variations, with the highest preva‑ lence in the United States and northern Europe, and the lowest prevalence in Japan (3) . Notably, ethnicity also has an impact on the prevalence of ovarian cancer and the incidence of mortality (1) . The highest incidence is observed in Caucasian patients with ~12 cases per 100,000 individuals, and the lowest incidence is observed in African‑American patients with~0.4 cases per 100,000 individuals (3) .  \nSymptoms. The term ‘silent killer’ has been given to ovarian cancer due to its high mortality rate, which is attributed to the inapparent tumor growth, delayed onset of symptoms and inad‑ equate screening, often leading to an advanced‑stage diagnosis in the firs","cbCaihhz0cG96Ufq","https://ap.wps.com/l/cbCaihhz0cG96Ufq","pdf",1833776,28,"English","# Introduction\n# Treatment of ovarian cancer\n## Novel treatment modalities\n## Future perspective and directions\n# Conclusion","[{\"question\":\"Why is ovarian cancer difficult to diagnose early?\",\"answer\":\"Non-specific or mild symptoms, delayed onset of symptoms, inadequate screening, and overlap with more common conditions often lead to advanced-stage diagnosis and diagnostic delays.\"},{\"question\":\"What topics does the review cover?\",\"answer\":\"The review covers epidemiology, clinical presentation, etiology, risk factors, staging, and diagnostic techniques, and also therapeutic approaches such as cytoreductive surgery and adjuvant treatments.\"},{\"question\":\"How do newer therapies relate to resistance and outcomes?\",\"answer\":\"Advancements in molecular profiling support novel therapeutic agents used in clinical practice or under investigation, aiming to improve management and survival while addressing resistance mechanisms.\"}]","Treatment of ovarian cancer - From the past to the new era - Review | PDF",1790189595,71,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc682c335b9cd1eda4d80b4e88254b35.webp",983,1357,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a208821ea6860fd90ce31818d219476e.webp",982,1356,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71e34b586e264f5069bb1a0e86757151.webp",981,1354,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0059bcb30d428005d453229545274183.webp",980,1353]